{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+and+Sitagliptin", "query": { "intervention": "Metformin and Sitagliptin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+and+Sitagliptin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T15:35:24.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01549964", "title": "Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glycemic Control" ], "interventions": [ { "name": "Fasiglifam (TAK-875)", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 916, "start_date": "2012-04", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-06-02", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 58, "location_summary": "Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01549964" }, { "nct_id": "NCT05161429", "title": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "DPP4", "type": "DRUG" }, { "name": "GLP-1 receptor agonist", "type": "DRUG" }, { "name": "Basal Insulin", "type": "DRUG" }, { "name": "SLGT2", "type": "DRUG" }, { "name": "SU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 550000, "start_date": "2021-07-01", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 5, "location_summary": "Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Beachwood", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161429" }, { "nct_id": "NCT00790348", "title": "Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 2 Diabetes" ], "interventions": [], "intervention_types": [], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2008-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-11-13", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790348" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT00484419", "title": "Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Hyperlipidemia" ], "interventions": [ { "name": "Colesevelam HCl", "type": "DRUG" }, { "name": "rosiglitazone maleate", "type": "DRUG" }, { "name": "sitagliptin phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 169, "start_date": "2007-05", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 20, "location_summary": "La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "San Antonio", "state": "California" }, { "city": "Chiefland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00484419" }, { "nct_id": "NCT00749190", "title": "BI 10773 add-on to Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 495, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 19, "location_summary": "Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749190" }, { "nct_id": "NCT01289990", "title": "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin 100mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2705, "start_date": "2011-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289990" }, { "nct_id": "NCT02405260", "title": "Add Glucokinase Activator to Target A1c", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "TTP399 400 mg", "type": "DRUG" }, { "name": "TTP399 800 mg", "type": "DRUG" }, { "name": "Sitagliptin 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "vTv Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 190, "start_date": "2015-03", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 20, "location_summary": "Mesa, Arizona • Tuscon, Arizona • Canoga Park, California + 16 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02405260" }, { "nct_id": "NCT05220917", "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Events", "Type2 Diabetes", "Renal Disease" ], "interventions": [ { "name": "SGLT2 inhibitor", "type": "DRUG" }, { "name": "DPP-4 inhibitor", "type": "DRUG" }, { "name": "GLP-1RA", "type": "DRUG" }, { "name": "2nd generation SU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 781430, "start_date": "2021-08-01", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05220917" }, { "nct_id": "NCT00729326", "title": "Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "exenatide", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 83, "start_date": "2008-08", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2015-04-09", "last_synced_at": "2026-09-27T15:35:24.857Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729326" } ] }